Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction

Bristol Myers Squibb (BMY) raised its 2026 revenue guidance to $49.75-$50.25 billion after Q3 results showed its newer-drug Growth Portfolio climbing 12% to $7.7 billion.

Total Q3 2026 revenue rose 7% to $13.1 billion, with the Growth Portfolio carrying the top-line gain. That is the core of the story: the company's pipeline of newer drugs is expanding fast enough to drive overall growth.

The headline blemish is earnings. Adjusted EPS fell 17% to $1.35. The company attributes the decline to upfront acquisition costs for pipeline drugs rather than weakness in the core business. Interpretation: this reads as a one-time investment charge tied to pipeline purchases, not an operating deterioration, though traders should note the EPS drop is real and will weigh on year-over-year comparisons.

The guidance raise matters most for positioning. Management is signaling confidence in its drug portfolio diversification strategy, and a higher revenue range suggests the Growth Portfolio's momentum is expected to persist through year-end.

Context on the tape: the CELGR ticker, tied to the Celgene contingent value rights, is the related security on this name's earnings reaction.